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Abstract
Introduction:  Upper  gastrointestinal  (UGI)  endoscopic  outcomes  are  seldom  described.
Objectives:  To  assess  UGI  endoscopy  performance  in  all  Portugal’s  National  Health  Service
hospitals and  assess  the  prevalence  of  premalignant  gastric  lesions.
Methods:  One  randomly  assigned  day,  cross-sectional  study  of  UGI  endoscopies.
Results: 28%  of  the  43  hospitals  invited  actually  participated  in  the  study,  reporting  a  total  of
123 UGI  endoscopies.  Exams  were  conducted  on  an  outpatient  basis  in  84%  of  cases  and  78%
required no  sedation.  The  commonest  indications  were  presence  or  suspicion  of  GI  bleeding
(20%), abdominal  pain  or  dyspepsia  (18%)  or  reﬂux  (12%).  Histological  diagnosis  of  atrophy  was
found in  19%  of  cases  (95%  CI  8--30%),  extensive  atrophy  or  intestinal  metaplasia  in  corpus  in
15% (5--25%)  and  positivity  for  Helicobacter  pylori  in  38%  (23--53%).  When  comparing  ﬁrst-time
vs. repeat  UGI  endoscopies,  no  differences  were  found  in  atrophy  (22%  vs.  14%,  p  =  0.49)  and
H. pylori  (44%  vs.  30%,  p  =  0.36)  nor  did  age  <  vs.  ≥  50  years  was  relevant  (11%  vs.  21%,  p  =  0.51
and 63%  vs.  31%,  p  =  0.10,  respectively).
Conclusions:  Most  UGI  endoscopies  carried  out  in  Portugal  are  safely  performed  on  an  outpatient
basis without  anaesthesia  and  15%  of  patients  have  extensive  atrophy  or  intestinal  metaplasia
in the  corpus  that  should  be  scheduled  for  endoscopic  surveillance  according  to  recent  guide-
lines. Although  the  participation  rate  was  low,  this  study  is  an  insight  for  further  decision
analysis studies  to  evaluate  UGI  endoscopy  as  a  surveillance  option  for  these  asymptomatic
at-risk patients.
© 2013  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Um  dia  de  endoscopia  digestiva  alta  num  país  do  sul  da  Europa
Resumo
Introduc¸ão:  Estudos  transversais  reportando  resultados  de  Endoscopia  Digestiva  Alta  (EDA)  são
raramente  descritos.
Objetivos:  Avaliar  o  desempenho  em  termos  de  EDA  em  hospitais  portugueses  do  Servic¸o
Nacional de  Saúde  e  a  prevalência  de  lesões  gástricas  pré-malignas.
Métodos:  Estudo  transversal  multicêntrico,  num  único  dia,  deﬁnido  aleatoriamente.
Resultados:  Participaram  no  estudo  28%  dos  43  hospitais  convidados,  compreendendo  um  total
de 123  EDA.  Os  exames  foram  realizados  em  ambulatório  em  84%  dos  casos  e  78%  não  neces-
sitaram de  sedac¸ão.  As  indicac¸ões  mais  frequentes  foram  presenc¸a  ou  suspeita  de  hemorragia
(20%), dor  abdominal  ou  dispepsia  (18%)  ou  reﬂuxo  (12%).  Histologicamente  foi  diagnosticada
atroﬁa gástrica  em  19%  dos  casos  (95%  IC  8--30%),  atroﬁa  extensa  ou  metaplasia  intestinal  no
corpo em  15%  (5--25%)  e  positividade  para  o  Helicobacter  pylori  (H.  Pylory)  em  38%  (23--53%).
Comparando  o  tipo  de  EDA  realizada,  primeira  vs.  repetic¸ão  não  foram  encontradas  diferenc¸as
no diagnóstico  de  atroﬁa  (22  vs.  14%,  p  =  0,49)  e  presenc¸a  de  H.  pylori  (44  vs.  30%,  p  =  0,36)
assim como  a  idade  <  vs.  ≥50  anos  não  foi  relevante  (11  vs.  21%,  p  =  0,51  e  63  vs.  31%,  p  =  0,10,
respetivamente).
Conclusões: A  maioria  das  EDA  em  Portugal  é  realizada  com  seguranc¸a  em  ambulatório  e  sem
anestesia.  Dos  pacientes,  15%  apresentam  atroﬁa  extensa  ou  metaplasia  intestinal  no  corpo  que
deve ser  orientada  para  vigilância  endoscópica  segundo  recomendac¸ões  recentes.  Embora  com
uma taxa  de  participac¸ão  baixa,  este  estudo  é  um  ponto  de  partida  para  estudos  de  análise
de decisão  que  avaliem  a  EDA  como  uma  opc¸ão de  vigilância  para  estes  doentes  de  alto  risco
assintomáticos.
© 2013  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos  reservados.
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introduction
ven  though  several  publications  have  reported  data  on
olonoscopy,  upper  gastrointestinal  (UGI)  endoscopic  pro-
edures  and  outcomes  are  seldom  described.
In  Portugal,  UGI  endoscopic  procedures  are  not  quan-
iﬁed  by  means  of  prospective  or  cross-sectional  studies
nd  existing  data  reproduce  only  hospital  databases  or  the
nnual  reports  that  Gastroenterology  Departments  provide
o  the  Portuguese  Medical  Association.  These  databases  are
ollected  retrospectively  and  focus  more  on  accountability
han  clinical  decisions.
As  Portugal  is  the  European  country  with  the  highest  inci-
ence  of  gastric  cancer  and  as  this  disease’s  prognosis  is
ighly  dependent  on  the  stage  at  diagnosis  (usually  in  an
dvanced  stage  requiring  drastic  and  costly  treatment),  it
s  crucial  to  have  data  on  prevalence  of  premalignant  gas-
ric  lesions.1,2 Furthermore,  patient  acceptance  to  undergo
 UGI  endoscopy  and  the  manner  in  which  these  exams  are
erformed  in  terms  of  associated  techniques,  complications
nd  use  of  sedation,  are  mandatory  to  quantify  costs  that
ight  be  relevant  in  further  economic  studies  that  con-
ider  UGI  endoscopy  for  population  screening  or  follow-up
f  asymptomatic  at-risk  patients  in  Portugal.
Some  reports  can  be  found  in  the  literature  on  Portuguese
atients,  but  only  on  speciﬁc  gastric  cancer  high-risk  groups;
o  the  best  of  our  knowledge,  no  data  have  yet  been  pub-
ished  on  the  prevalence  of  gastric  cancer  precursor  lesions
t  a  national  level.3--7
The  primary  aim  of  our  study  was  therefore  to  assess,
or  a  single  day,  all  the  UGI  endoscopies  performed  in  all
r
p
r
tortugal’s  National  Health  Service  hospitals.  As  a secondary
bjective  we  aimed  to  assess  the  prevalence  of  gastric  pre-
ursor  lesions  at  a  population  basis  by  means  of  a  national
ulticentre  cross-sectional  study.
aterials and methods
ll  43  National  Health  Service  Portuguese  hospitals  with  Gas-
roenterology  Departments  registered  with  the  Portuguese
ociety  of  Digestive  Endoscopy  were  invited  to  participate
n  this  study  by  sending  all  their  UGI  endoscopy  reports  from
 randomly  assigned  day.  If  biopsies  were  performed,  the
esults  of  the  relevant  histopathology  diagnosis  were  also
equested.
Invitation  letters  were  sent  several  months  before  the
ate  chosen  for  the  study  and  all  Departments  were  invited
o  report  all  UGI  endoscopies  performed  on  a  single  day
November  17th,  2011).
Inclusion  criteria  were  the  completion  of  an  already
cheduled  UGI  endoscopy  in  a  National  Service  Hospital  and
 signed  informed  consent,  speciﬁc  to  the  study.  Exclu-
ion  criteria  were  emergency  exams,  failure  to  provide
nformed  consent  or  any  contraindication  to  performing  a
GI  endoscopy.
The  conﬁdentiality  of  all  records  was  ensured  by  remov-
ng  the  names  of  patients,  doctors  and  nurses  from  the
eports  before  they  were  sent  to  the  main  investigator.  Also,
ermission  for  compilation  of  multicenter  national  data  was
equested  from  and  granted  by  the  Portuguese  Data  Pro-
ection  Authority  (Authorisation  4639/2010).  As  the  study
99
Table  1  Description  of  UGI  endoscopies  and  patients’  main
characteristics.
Item  Resulta
Number  of  endoscopies  (mean  per
centre  ±  standard  deviation)
123  (10  ±  4)
Previous  history  of  digestive  neoplasia  12%  (6--18)
Concomitant  medication  with
antiplatelet  or  anticoagulant
agents
15%  (9--21)
Outpatients  84%  (78--90)
First  performance  of  UGI  endoscopy  50%  (41--59)
Main  indications
•  Haemorrhage  and/or  anaemia 20%  (13--27)
• Abdominal  pain  or  dyspepsia  18%  (11--25)
• Reﬂux  12%  (6--18)
Associated  techniques
• Biopsies  45%  (36--54)
• Other  15%  (9--21)
• Injection  3.9%  (0.5--7.3)
• Polypectomy  3.1%  (0.04--6.2)
• Dilation  3.1%  (0.04--6.2)
Use of  sedation  22%  (15--29)
• By  a  gastroenterologist  (moderate
sedation  with  Midazolam)
10%  (5--15)
• By  a  anaesthesiologist  (deep
sedation  with  Propofol)
12%  (6--18)
Complicationsb 2%  (0.5--4.5)
UGI-upper gastrointestinal.
a All results are reported as percentages with 95% conﬁdence
intervals except for the number of endoscopies.
b Complications were all minor haemorrhage cases associated
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involved  the  performance  of  only  already-scheduled  endo-
scopic  exams,  with  no  additional  exams  or  measures,  no
Ethics  Committee  approval  was  required  but  prior  approval
was  obtained  from  the  Portuguese  Society  of  Digestive
Endoscopy.
Reports  included  information  on  the  patient’s  gender  and
age,  exam  indications,  main  endoscopic  ﬁndings  and  conclu-
sions,  procedures  performed  (including  sedation,  biopsies
and  therapy)  and  histopathological  results,  if  applicable.
Selection  bias  was  minimised  by  informing  the  Depart-
ments  of  the  study  date  only  a  week  beforehand,  to  prevent
major  changes  in  the  daily  schedule  and  all  Departments
were  instructed  to  proceed  as  usual  in  their  daily  practice.
No  exclusion  criteria  were  deﬁned  for  gastroenterologist
experience,  type  of  endoscope  used,  indication  for  exam
(but  emergency  cases  were  excluded),  performance  or  not
of  biopsies  or  minimum  number  of  cases  needed  to  partici-
pate.
No  sample  size  was  predeﬁned  for  this  study  and  the
results  reported  for  the  continuous  variables  are  the  means
and  standard  deviations  while  proportions  are  reported  as
percentages  with  95%  conﬁdence  intervals  (CI).  Comparative
statistical  analysis  used  Student’s  t-test  for  the  continuous
variables  and  Pearson’s  Chi-square  test  or  Fisher’s  Exact  test
for  the  dichotomous  variables,  as  appropriate,  with  p  =  0.05
representing  statistical  signiﬁcance.
Results
Of  all  43  Portuguese  National  Health  Service  hospitals  with  a
Gastroenterology  Department,  12  (28%)  participated  in  the
study.  The  hospitals  were  located  all  over  mainland  Portugal,
representing  the  north  (2  hospitals),  centre  (2  hospitals),
the  capital,  Lisbon,  (4  hospitals),  south  (2  hospitals),  plus
the  Azores  (2  hospitals).  The  total  number  of  reported  UGI
endoscopies  was  123,  providing  a  median  of  10  per  Depart-
ment.  No  data  were  collected  on  eligibility  and  inclusion
rate  per  centre.  The  main  results  of  the  exams  are  presented
in  Table  1.
Most  UGI  endoscopies  were  performed  as  outpatient  pro-
cedures  (84%),  most  required  no  type  of  sedation  (78%)  and
50%  of  the  participants  were  undergoing  a  UGI  endoscopy
for  the  ﬁrst  time.  Most  UGI  endoscopies  were  diagnos-
tic  but  in  15%  of  them  at  least  one  additional  technique
was  performed  (injection,  polypectomy,  dilation  or  stent
placement).  Most  of  the  exams  had  no  complications  (98%)
with  only  3  cases  of  minor  haemorrhage  after  endoscopic
polypectomy,  all  resolved  without  any  requirement  for  blood
transfusion,  surgery  or  inpatient  care.
The  most  frequent  indications  were  presence  or  suspicion
of  haemorrhage  (20%),  abdominal  pain  or  dyspepsia  (18%)  or
reﬂux  (12%).  These  indications  were  the  ones  reported  by
the  attending  endoscopists,  even  when  emergency  exams
were  excluded  from  the  study  (probably  the  haemorrhage
cases  are  related  to  complaints  of  anaemia  or  melaena  with-
out  haemodynamic  instability).  The  exam  was  considered
abnormal  in  77%  of  cases,  with  most  frequent  endoscopic
diagnosis  being  ‘‘gastritis’’  (28%),  ‘‘gastric  atrophy’’  (14%)
and  oesophagitis  (11%).  When  examining  the  cases  that
entailed  an  additional  histology  report,  a  histopathological
diagnosis  of  gastritis  was  found  in  56%  of  patients  (95%  CI:
w
o
p
twith polypectomy, managed by endoscopy without any need for
blood transfusion, surgery or inpatient care.
2--70%)  with  atrophy  in  19%  (95%  CI:  8--30%),  extensive  atro-
hy  or  intestinal  metaplasia  in  corpus  in  15%  (95%  CI  5--25%)
nd  positivity  for  H.  pylori  in  38%  (95%  CI:  23--53%).
When  comparing  ﬁrst-time  UGI  endoscopy  cases  with  a
epeated  exam,  no  differences  were  found  in  terms  of  histo-
ogical  diagnosis  of  gastritis  (56%  vs.  57%,  p  =  0.91),  atrophy
22%  vs.  14%,  p  =  0.71),  extensive  atrophy  or  intestinal  meta-
lasia  (11%  vs.  19%,  p  =  0.68)  or  H.  pylori  positivity  (44%  vs.
0%,  p  =  0.36)  (Table  2).  Also,  when  comparing  the  inﬂu-
nce  of  age  on  the  same  diagnosis  (age  <  vs.  ≥  50  years),
he  respective  proportions  were  not  statistically  signiﬁcant
etween  groups:  56%  vs.  56%  for  gastritis;  21%  vs.  11%  for
trophy,  11%  vs.  15%  for  extensive  atrophy  or  intestinal
etaplasia  and  63%  vs.  31%  for  H.  pylori  positivity  (Table  3).
iscussion
utcome  assessment  in  the  ﬁeld  of  UGI  endoscopy  is  sel-
om  reported  in  the  scientiﬁc  literature  and  information  is
carce  worldwide.  With  this  one-day  cross-sectional  study
e  intended  to  conduct  the  very  ﬁrst  national  assessment
f  UGI  endoscopy  practice  and  to  assess  the  prevalence  of
remalignant  gastric  conditions  or  lesions  on  a  multicen-
er  population  basis.  This  is  very  important  to  improving
100  M.  Areia  et  al.
Table  2  Clinical  and  histological  ﬁndings  according  to  performance  of  UGI  endoscopy.
First  UGI
endoscopy
Follow-up  UGI
endoscopy
p
Age  (mean  ±  standard  deviation)  61  ±  18  60  ±  14  0.58*
Male  sex  54%  50%  0.65**
Previous  GI  tract  neoplasia  3%  20%  0.004**
Antiplatelet  or  anticoagulant  therapy  17%  12%  0.43**
Use  of  sedation  18%  26%  0.30**
Performance  of  biopsies  51%  39%  0.18**
Gastritis  (n  =  48)  56%  57%  0.91**
Atrophy  (n  =  48) 22%  14%  0.71***
Corpus  atrophy  or  intestinal  metaplasia  (n  =  48) 11%  19%  0.68***
H.  pylori  positive  (n  =  40) 44%  30%  0.36**
UGI, upper gastrointestinal; GI, gastrointestinal.
* Student’s t-test.
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nowledge  of  the  actual  prevalence  of  these  lesions  as  the
nal  disease,  gastric  cancer,  is  still  a  health  problem  in  Por-
ugal,  due  its  high  incidence  and  mortality  rates.
In  our  country,  where  a  high  prevalence  of  gastric
esions  and  H.  pylori  was  expected,  our  results  showed  that
mong  patients  where  gastric  biopsies  were  performed,  a
istopathological  diagnosis  of  atrophy  was  detected  in  19%
f  cases  (95%  CI:  9--29%),  extensive  atrophy  or  intestinal
etaplasia  in  corpus  in  15%  (95%  CI  5--25%)  and  positivity
or  H.  pylori  was  present  in  38%  (95%  CI:  25--51%).  This
eans  that  at  least  one  ﬁfth  of  the  observed  population
as  a  premalignant  gastric  condition  and  that  two  ﬁfths  are
ositive  for  H.  pylori. Also,  15%  of  patients,  usually  aged
ver  50,  presented  with  atrophy  or  intestinal  metaplasia
xtending  to  the  corpus  and  these  are  the  ones  that  should
e  scheduled  for  an  endoscopic  surveillance  according  to
ecent  guidelines  on  evaluating  gastric  premalignant  condi-
ions  or  lesions.8
Considering  that  UGI  endoscopy  is  the  key  exam  for  gas-
ric  cancer  diagnosis  and  could  prove  to  be  a  relevant  option
or  surveillance  of  asymptomatic  high-risk  patients,  it  was
ery  reassuring  to  conclude  that  most  UGI  endoscopies  were
afely  performed,  on  an  outpatient  basis  (84%),  according  to
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Table  3  Clinical  and  histological  ﬁndings  according  to  age  at  UG
Age
Male  sex  44%
Previous  GI  tract  neoplasia  4%
Antiplatelet  or  anticoagulant  therapy  0%
Use  of  sedation  20%
Performance  of  biopsies  44%
Gastritis  (n  =  48)  56%
Atrophy  (n  =  48)  11%
Corpus  atrophy  or  intestinal  metaplasia  (n  =  48)  11%
H.  pylori  positive  (n  =  40)  63%
UGI, upper gastrointestinal; GI, gastrointestinal;
* Pearson’s Chi-square test.
** Fisher’s Exact test.orrect  indications,  without  any  sort  of  sedation  or  anaes-
hesia  (used  in  only  22%  of  patients),  and  that  most  exams
ere  supplemented  with  biopsies  (45%)  in  accordance  with
urrent  recommendations.8--10
Comparing  results  for  patients  undergoing  their  very  ﬁrst
GI  endoscopy  versus  a repeat  exam,  the  only  statistically
igniﬁcant  difference  was  in  the  presence  of  a previous  his-
ory  of  GI  tract  neoplasia  (as  expected)  and,  although  not
igniﬁcant,  more  ﬁrst  time  endoscopies  were  supplemented
ith  biopsies  (again  as  expected).  When  comparing  results
etween  patients  under  and  over  50  years  old,  the  only
tatistically  relevant  difference  was  the  higher  prevalence
f  antiplatelet  or  anticoagulant  medication  in  the  older
roup  and  a not  signiﬁcant  lower  prevalence  in  this  group
f  H.  pylori, possibly  due  to  previous  eradication  treatment
not  accessed  in  this  study  as  already  mentioned).
The  study  was  designed  to  be  performed  without  any
isturbance  in  the  participating  centres  and  without
ny  speciﬁc  requirement  beyond  the  scheduled  examina-
ion,  so  that  it  would  not  be  detrimental  to  patients.
here  was  no  intention  to  collect  additional  materi-
ls,  since  it  was  meant  to  be  as  close  as  possible  to
eal  practice.  These  premises  would  possibly  encourage
I  endoscopy  performance.
 <  50  years  Age  ≥  50  years  p
 54%  0.37*
 14%  0.21*
 19%  0.02*
 22%  0.79*
 45%  0.94*
 56%  0.96*
 21%  1.0**
 15%  1.0**
 31%  0.13*
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engagement  of  gastroenterology  departments  and  patients
and  could  provide  an  unbiased  prevalence  rate,  as  opposed
to  ﬁndings  from  studies  on  selected  populations.
The  choice  of  one-day  only  collection  data,  established
at  fairly  short  notice  (instead  of  several  days  or  weeks)
was  chosen  to  avoid  any  selection  bias  by  preventing  the
inclusion  of  more  patients  simply  because  the  study  was
being  conducted,  which  could  bias  the  ﬁnal  results  towards  a
larger  number  of  exams,  a  higher  rate  of  more  serious  cases
or  the  introduction  of  speciﬁc  therapeutic  exams.  No  signif-
icant  bias  was  considered  and  the  ﬁnal  results  attained  just
need  to  be  contextualised  due  to  the  small  sample  size.  The
very  low  participation  rate  of  just  24%  may  obviously  par-
tially  jeopardise  the  precision  and  external  validity  of  the
study  results.  Still,  this  participation  rate  is  not  very  dif-
ferent  from  other  survey  studies,11--13 and  the  methods  of
the  study  and  the  national  population  basis  without  restric-
tive  inclusion  criteria  used  can  easily  be  implemented  in  any
country.  The  rates  obtained  also  need  to  be  contextualised
for  a  European  country  with  a  high  gastric  cancer  incidence
rate.
In  conclusion,  most  UGI  endoscopies  are  safely  performed
in  our  country.  About  a  ﬁfth  of  the  observed  population  has
gastric  atrophy,  two  ﬁfths  are  positive  for  H.  pylori  and  15%
have  extensive  atrophy  or  intestinal  metaplasia  in  the  cor-
pus,  which  should  be  scheduled  for  endoscopic  surveillance,
according  to  current  guidelines.  Further  decision  analysis
studies  are  needed  to  evaluate  UGI  endoscopy  as  a  surveil-
lance  option  for  these  asymptomatic  at-risk  patients.
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